Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.48 |
| ▸ | NOS2 | P35228 | 3/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | TERT | O14746 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742429 | 0.85 | TDP1 (0.41) | NOS3NOS2NOS1TERTPOLB | |
| SCHEMBL3266109 | 0.83 | MAPT (0.53) | NOS3NOS2TERTPOLBMAPT | |
| SCHEMBL11037706 | 0.77 | HTR6 (0.47) | NOS3NOS2MAPTALDH1A1TDP1 | |
| SCHEMBL12411157 | 0.77 | HRH4 (0.51) | NOS3NOS2NOS1GAAALDH1A1 | |
| SCHEMBL12658527 | 0.76 | TDP1 (0.35) | NOS3NOS2NOS1TERTPOLB | |
| SCHEMBL15360174 | 0.76 | ADORA1 (0.36) | NOS3NOS2NOS1TERTMAPT | |
| SCHEMBL12106760 | 0.76 | MAPT (0.45) | NOS3NOS2NOS1POLBMAPT | |
| SCHEMBL12499637 | 0.74 | NOS3 (0.58) | NOS3NOS2TERTPOLBMAPT | |
| SCHEMBL11403178 | 0.74 | MAPT (0.47) | NOS3NOS2NOS1MAPTGAA | |
| SCHEMBL23999695 | 0.73 | NOS3 (0.54) | NOS3NOS2NOS1TERTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023939-A1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (CN) | 2023-03-02 | — | — | WO | disclosed |
| EP-3555070-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme Inc (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018118842-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | NOS3 3545/4885NOS2 3122/4885NOS1 3880/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | NOS3 3545/4885NOS2 3122/4885NOS1 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.